Bausch & Lomb-2026-JPM.pdf

1、1 1J.P.Morgan44th Annual Healthcare ConferenceJanuary 12,20262 2Forward-Looking Statements;Non-GAAP Information2Forward-Looking StatementsThis presentation contains forward-looking information and statements,within the meaning of applicable securities laws(collectively,“forward-looking statements”),

2、including,but not limited to,statements regarding future prospects and performance of Bausch+Lomb Corporation(“Bausch+Lomb”,the“Company”,“we”,“us”,or“B+L”),our three year financial targets(including targets for Company and segment level cc revenue CAGRs,projected Adj.EBITDA margin(excl.Acq.IPR&D),an

3、nual adj.EPS(excl.Acq.IPR&D)growth rates,adjusted cash flow from operations to Adj.EBITDA(excl.Acq.IPR&D)conversion and net leverage),our strategic plan for meeting our financial targets and the steps thereof,our anticipated growth drivers and the expected timing and impact thereof,our focus on pipe

4、line innovation,the success of our pipeline products and R&D programs,the existence of potential game changers in our pipeline and our ability to be the best in class or first product to market of its kind,anticipated approval and launch dates for our pipeline products,our estimates for potential pe

5、ak sales for our pipeline products,franchises and businesses,our ability to outperform the market,our ability to expand into new categories and new and existing markets and to address new indications and disease states,our ability to successfully launch next generation versions of our existing produ

6、cts,our ability to focus on and have success with disruptive innovation,the expected market acceptance and performance for certain of our pipeline products,the expected market size for certain of the markets in which we expect to have products,and the timing of commencement and completion of clinica